Women with the Alzheimer's risk marker ApoE4 lose Aβ-specific CD4 + T cells 10-20 years before men

Translational Psychiatry

Volumn 4, Issue , 2014, Pages

  Begum, A N ^a   Cunha, C ^a   Sidhu, H ^a,b   Alkam, T ^a   Scolnick, J ^c,e   Rosario, E R ^d   Ethell, D W ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ARROWHEAD REGIONAL MEDICAL CENTER   (United States)

^d Casa Colina Centers for Rehabilitation   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; CYTIDINE PHOSPHATE; ESTROGEN; GENOMIC DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOSIALIN;

ADAPTIVE IMMUNITY; ADULT; AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CONTROLLED STUDY; DENDRITIC CELL; EMBRYO; EMBRYONIC STEM CELL; FEMALE; FOLLOW UP; GENETIC RISK; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR WEIGHT; MYELOID PROGENITOR CELL; PLURIPOTENT STEM CELL; SEX DIFFERENCE; VERY ELDERLY; ANTIGEN SPECIFICITY; CELL DIVISION; CELL PHAGOCYTOSIS; CELL PROLIFERATION; CLINICAL ARTICLE; HIGH RISK POPULATION; MYELOID DENDRITIC CELL; PERIPHERAL LYMPHOCYTE; POSTMENOPAUSE;

EID: 84904512717     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.51     Document Type: Article

References (53)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 2007; 3: 186-191. (Pubitemid 46825511)
2. Thies W, Bleiler L. 2012 Alzheimer's disease facts and figures. Alzheimers Dement 2013; 9: 208-245.
3. Selkoe DJ. Resolving controversies on the path to Alzheimer's therapeutics. Nat Med 2011; 17: 1060-1065. Erratum in: Nat Med 17, 1693 (2011). Nat Med 17, 1521 (2011).
4. Holtzman DM, Mandelkow E, Selkoe DJ. Alzheimer disease in 2020. Cold Spring Harb Perspect Med 2012; 2: 11.
5. Savonenko AV, Melnikova T, Hiatt A, Li T, Worley PF, Troncoso JC et al. Alzheimer's therapeutics: translation of preclinical science to clinical drug development. Neuropsychopharmacology 2012; 37: 261-277.
6. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981. (Pubitemid 23069980)
7. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008; 9: 768-778.
8. Henderson VW. Estrogen, cognition, and a woman's risk for Alzheimer's disease. Am J Med 1997; 103: 11-18.
9. Bretsky PM, Buckwalter JG, Seeman TE, Miller CA, Poirier J, Schellenberg GD et al. Evidence for an interaction between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13: 216-221. (Pubitemid 30011379)
10. Nelson PT et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381.
11. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. 1985. Proc Natl Acad Sci USA 82: 4245-4249. (Pubitemid 15053619)
12. O'Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011; 34: 185-204.
13. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 2012; 71: 362-381.
14. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177. (Pubitemid 29327547)
15. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J et al. A-beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985, Erratum in: Nature 412, 660 (2001). (Pubitemid 32101645)
16. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO et al. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452. (Pubitemid 36460079)
17. Ethell DW, Shippy D, Cao C, Cracchiolo JR, Runfeldt M, Blake B et al. Aβ-specific T cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis 2006; 23: 351-361. (Pubitemid 44097033)
18. Cao C, Arendash GW, Dickson A, Mamcarz MB, Lin X, Ethell DW et al. Aβ-specific T cells are sufficient for beneficial effects in the APP+PS1 mouse model for Alzheimer's disease. Neurobiol Dis 2009; 34: 63-70.
19. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010; 9: 749-751.
20. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919. (Pubitemid 30644751)
21. Castellani RJ, Perry G. Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch Med Res 2012; 43: 694-698.
22. Editorial. Colombia at the centre of preclinical AD research. Lancet Neurol 2012; 11: 567.
23. Frisoni GB, Trojanowski JQ. Primary or secondary prevention for AD: who cares? Lancet Neurol 2012; 11: 661-662.
24. Aisen PS, Vellas B. Passive immunotherapy for Alzheimer's disease: What have we learned, and where are we headed? J Nutr Health Aging 2013; 17: 49-50.
25. Oh ES, Troncoso JC, Fangmark Tucker SM. Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease. Neuromolecular Med 2008; 10: 195-207.
26. Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med 2010; 207: 1067-1080.
27. Schwartz M, Kipnis J. A conceptual revolution in the relationships between the brain and immunity. Brain Behav Immun 2011; 25: 817-819.
28. Kipnis J, Gadani S, Derecki NC. Pro-cognitive properties of T cells. Nat Rev Immunol 2012; 12: 663-669.
29. Trowsdale J, Knight JC. Major histocompability complex genomics and human disease. Annu Rev Genomics Hum Genet 2013; 24: 301-323.
30. Haars R, Kroneneberg M, Gallatin WM, Weissman IL, Owen FL, Hood L et al. Rearrangement and expression of T cell antigen receptors and gamma genes during thymic development. J Exp Med 1986; 164: 1-24. (Pubitemid 16069218)
31. Koch U, Radtke F. Mechanisms of T cell development and transformation. Annu Rev Cell Dev Biol 2011; 27: 539-562.
32. Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J et al. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 2010; 28: 79-105.
33. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27: 591-619.
34. Kong Chen K, Kolls JK. T cell-mediated host immune defenses in the lung. Annu Rev Immunol 2013; 31: 605-633.
35. Daigneault M, Preston JA, Marriott HM, Whyte MK, Dockrell DH. (2010). The identification of markers of macrophage differentiation in PMA-stimulated THP- -1 cells and monocyte-derived macrophages. PLoS One 2010; 5: e8668.
36. Le Nouën C, Hillyer P, Munir S, Winter CC, McCarty T, Bukreyev A et al. Effects of human respiratory syncytial virus, metapneumovirus, parainfluenza virus 3 and influenza virus on CD4+ T cell activation by dendritic cells. PLoS One 2010; 5: e15017.
37. Schmidt T, Dirks J, Enders M, Gärtner BC, Uhlmann-Schiffler H, Sester U et al. CD4+ T-cell immunity after pandemic influenza vaccination cross-reacts with seasonal antigens and functionally differs from active influenza infection. Eur J Immunol 2012; 42: 1755-1766.
38. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissuespecific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872. (Pubitemid 34118370)
39. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-1443.
40. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA 2001; 98: 5856-5861. (Pubitemid 32435732)
41. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 2001; 68: 1239-1244.
42. Tamboli I Y, Barth E, Christian L, Siepmann M, Kumar S, Singh S et al. (2010) Statins promote the degradation of extracellular amyloid {beta}-peptide by microglia via stimulation of exosome-associated insulin-degrading enzyme (IDE) secretion. J Biol Chem 2010; 285: 37405-37414.
43. Naylor K, Li G, Vallejo A.N, Lee W.W, Koetz K, Bryl E et al. The influence of age on T cell generation and TCR diversity. J Immunol 2005; 174: 7446-7452. (Pubitemid 40705717)
44. Wong C, Goldstein DR. Impact of aging on antigen presentation cell function of dendritic cells. Curr Opin Immunol 2013; 25: 535-541.
45. Pereira LF, de Souza AP, Borges TJ, Bonorino C. Impaired in vivo CD4+ T cell expansion and differentiation in aged mice is not solely due to T cell defects: decreased stimulation by aged dendritic cells. Mech Ageing Dev 2011; 132: 187-194.
46. Baron AM, Pike CJ. Sex hormones, aging and Alzheimer's disease. Front Biosci 2012; 4: 976-997.
47. Henderson VW, Brinton RD. Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy. Prog Brain Res 2010; 182: 77-96.
48. Carroll JC, Rosario ER. The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease. Curr Alzheimer Res 2012; 9: 18-34.
49. Sakiani S, Olsen NJ, Kovacs WJ. Gonadal steroids and humoral immunity. Nat Rev Endocrinol 2013; 9: 56-62.
50. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem Biophys Res Commun 1993; 192: 359-365.
51. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB et al. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 2008; 118: 4002-4013.
52. Kline A. (2012) Apolipoprotein E, amyloid-β clearance and therapeutic opportunities in Alzheimer's disease. Alzheimers Res Ther 2012; 4: 32.
53. Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE et al. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012; 335: 1503-1506.